Madhuri Kadiyala, MD
Hematology-Oncology · Chandler, AZNPI 1467426320
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $699 of the $865 with a category attached, or 80.7%. It is spread thinly across 23 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $506 and has fallen 95.9% since, to $21 in 2025.
Across 46 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$141
- Pharmacyclics LLC, An Abbvie Company$114
- Sanofi$79
- AbbVie$67
- Amgen$59
- AMAG Pharmaceuticals, Inc.$38
- plus $367 from 17 others
What the payments were for
- Food & beverage$69981%
- Education$16719%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 7 | $141 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $114 |
| Sanofi | 5 | $79 |
| AbbVie | 3 | $67 |
| Amgen | 2 | $59 |
| AMAG Pharmaceuticals, Inc. | 3 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Seagen Inc. | 2 | $31 |
| Bayer | 2 | $28 |
| Foundation Medicine, Inc. | 2 | $28 |
| Pfizer | 1 | $25 |
| Puma Biotechnology, Inc. | 2 | $25 |
| AstraZeneca(2 entities) | 2 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| GSK | 1 | $20 |
| Novartis | 1 | $19 |
| Tesaro, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Gilead | 1 | $12 |
| Verastem, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
How this compares
Too few hematology-oncology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology-oncology in Chandler
- Madappa KundrandaGilbert$71K
- Navjeet GandhokPeoria$19K
- Amol RakkarGlendale$18K
- Alejandro Recio BoilesTucson$5K
- Valerie IsraelLake Havasu City$4K
- James ChoiGlendale$4K
- Srivyshnavi NarraSun City$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.